Scalper1 News
The second half of August is usually a desert for business news, but the FDA schedule is year-round. Several important drugs are up for approval decisions this month, which could provide some upside for three biotech stocks that have recently been suffering. Getting the most attention will likely be Repatha, Amgen’s (AMGN) cholesterol drug. It’s expected to be approved by Aug. 27. Repatha is a PCSK9 inhibitor similar to Praluent, the drug from Scalper1 News
Scalper1 News